完整後設資料紀錄
DC 欄位語言
dc.contributor.authorLin, Chien-Mingen_US
dc.contributor.authorHuang, Hui-Lingen_US
dc.contributor.authorChu, Fang-Yingen_US
dc.contributor.authorFan, Hueng-Chuenen_US
dc.contributor.authorChen, Hung-Anen_US
dc.contributor.authorChu, Der-Mingen_US
dc.contributor.authorWu, Li-Weien_US
dc.contributor.authorWang, Chung-Chingen_US
dc.contributor.authorChen, Wei-Liangen_US
dc.contributor.authorLin, Shih-Huaen_US
dc.contributor.authorHo, Shinn-Yingen_US
dc.date.accessioned2019-04-03T06:38:33Z-
dc.date.available2019-04-03T06:38:33Z-
dc.date.issued2015-05-15en_US
dc.identifier.issn1932-6203en_US
dc.identifier.urihttp://dx.doi.org/10.1371/journal.pone.0125421en_US
dc.identifier.urihttp://hdl.handle.net/11536/124811-
dc.description.abstractBackground The relationship between diabetes mellitus (DM) and cancer incidence has been evaluated in limited kinds of cancer. The effect of anti-diabetic therapy (ADT) on carcinogenesis among diabetic patients is also unclear. Materials and Methods Using population-based representative insurance claims data in Taiwan, 36,270 DM patients and 145,080 comparison subjects without DM were identified from claims from 2005 to 2010. The association between the top ten leading causes of cancer-related death in Taiwan and DM was evaluated. Whether ADT altered the risk of developing cancer was also investigated. Results Incidence of cancer at any site was significantly higher in patients with DM than in those without (p<0.001). The risk of carcinogenesis imparted by DM was greatest in gastroenterological malignancies (liver, pancreas, and colorectal cancer) as well as lung, breast and oral cancer (p<0.001). Among the oral types of ADT, metformin decreased the risk of lung and liver cancer, but had less effect on reducing the risk of colorectal cancer. alpha-glucosidase inhibitor decreased the risk of developing liver, colorectal, and breast cancer. Apart from intermediateacting insulin, rapid-acting, long-acting, and combination insulin treatment significantly reduced the overall cancer risk among all DM patients. In subgroup analysis, long-acting insulin treatment significantly decreased the risk of lung, liver, and colorectal cancer. Conclusion Our results supported the notion that pre-existing DM increases the incidence of gastroenterological cancer. ADT, especially metformin, alpha-glucosidase inhibitor, and long-acting insulin treatment, may protect patients with DM against these malignancies. It is crucial that oncologists should closely collaborate with endocrinologists to provide an optimal cancerspecific therapy and diabetic treatment to patients simultaneously with cancer and DM.en_US
dc.language.isoen_USen_US
dc.titleAssociation between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1371/journal.pone.0125421en_US
dc.identifier.journalPLOS ONEen_US
dc.citation.volume10en_US
dc.citation.issue5en_US
dc.citation.spage0en_US
dc.citation.epage0en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.department生物資訊及系統生物研究所zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.contributor.departmentInstitude of Bioinformatics and Systems Biologyen_US
dc.identifier.wosnumberWOS:000354916100026en_US
dc.citation.woscount15en_US
顯示於類別:期刊論文


文件中的檔案:

  1. f7653d019ae518c882ea4f3316817b25.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。